Highest-materiality recent filing
Aug 12, 2026: issued $714,285.72 senior secured convertible note to Ascent for $650,000, 7% interest, matures Aug 12, 2027, with OID.
Profusa Q2 net loss $8.8M; cash $719K; progress on G3 option
Net loss Q2 2026 $(8.8)M vs $(2.2)M year-ago; six-month loss $(12.2)M vs $(5.1)M.
Profusa announces 1-for-4 reverse stock split effective Aug 17, 2026
1-for-4 reverse stock split effective 12:01 a.m. ET Aug 17, 2026; trading on Nasdaq under PFSA with new CUSIP 74319X405.
Profusa signs option to acquire G3 Vision Labs; G3 had ~$111M 2025 revenue
Option to acquire G3 Vision Labs and its subsidiaries (Med Screen, Dominion, Acutis) for equity consideration.
Non-binding term sheet to acquire a private diagnostics/toxicology testing company; 2025 net revenues estimated at ~$111M (unaudited).
Profusa announces 1-for-25 reverse stock split effective July 7, 2026
Reverse split ratio 1:25, effective 12:01 a.m. ET on July 7, 2026.
Profusa shareholders approve reverse stock split, asset acquisition, and equity plan amendments
Elected Lauren Chung as Class I director with 631,502 FOR votes.
Profusa amends equity line terms with Ascent, introduces price adjustment and cap
Advance Notices limited to 9.99% of outstanding shares, capped at $200,000 per notice.
Amendment removes Section 4.6 requiring issuance of 12% fully diluted shares to CEO and CFO as retention.
Advance Notice submitted to Ascent Partners Fund LLC for purchase of common stock under equity line arrangement.
Profusa transfers to Nasdaq Capital Market on May 15, 2026, under panel compliance plan
Transfer to Nasdaq Capital Market effective May 15, 2026, per hearings panel confirmation.
Profusa granted Nasdaq exception to continue listing; transfer to Capital Market by July 6, 2026
Nasdaq Hearings Panel granted exception to continue listing; must comply with Bid Price Rule and Equity Rule by July 6, 2026.
Profusa faces Nasdaq delisting for MVPHS failure; amends debt and warrant terms
Received Nasdaq notice of non-compliance with $15M MVPHS Rule; deadline missed April 27, 2026; response due May 5.
Profusa acquires PanOmics platform assets for $30M in convertible preferred stock
Purchase price $30M via Series A Convertible Preferred Stock, convertible to common after 1 year.
Profusa Issues $1.11M Convertible Note and Warrant to Ascent Partners Fund LLC
Issued $1,111,111.11 principal Senior Secured Convertible Promissory Note to Ascent Partners Fund LLC for $1,000,000 purchase price, maturing April 20, 2027, with 12% annual interest.
Profusa signs LOI to buy PanOmics assets for $30M equity; issues $555k convertible note
Non-binding LOI to acquire Bio Insights' PanOmics assay for $30M in stock (460k common + 59.54M conversion shares) plus 3% annual net revenue royalty.
Profusa extends $2.5M promissory note maturity to Dec 31, 2026
Amendment effective March 20, 2026 extends maturity of note from NorthView Sponsor I LLC.
Profusa receives Nasdaq delisting notice; terminates Bitcoin treasury strategy, liquidates holdings
Nasdaq Global Market delisting notice for failure to meet $50M MVLS and $1.00 bid price; deadline March 10, 2026 missed.
Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI
Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).
Profusa announces 1-for-75 reverse stock split effective Feb 9, 2026
Reverse stock split ratio 1:75; effective 12:01 a.m. ET on Feb 9, 2026.
Profusa shareholders approve reverse stock split authorization up to 1-for-200
Proposal to authorize Board to effect reverse splits at ratios 1-for-30 to 1-for-200 before Jan 27, 2028 passed with 30.8M For, 6.0M Against.
Profusa enters Amendment No. 3 to SPA; third tranche up to $5.56M principal, floor price $0.35
Third tranche: up to $5,555,556 principal for $5M purchase price; requires zero balance on prior tranches, Nasdaq listing, and stockholder approval.
SPA Amendment lowers Floor Price to $0.111/share for up to 13.65M shares during Modification Period ending upon reverse stock split (expected Jan 2026).
Profusa cuts net debt to $14M, gives 2026-2030 revenue targets
Net debt reduced from $48M to $16M in Q3 2025 and to $14M as of Oct 31, 2025.
Profusa receives Nasdaq deficiency notice for MVPHS below $15M; 180-day cure period until April 2026
Nasdaq notified Profusa on Oct 27, 2025 that MVPHS was below $15M for 30 consecutive business days from Sep 12 to Oct 24, 2025.
Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026
EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.
Profusa publishes updated investor presentation; no material specifics in filing excerpt
Updated investor presentation posted on company website on October 20, 2025.
Profusa shareholders approve doubling authorized shares to 600M and conversion issuance
Authorized common shares increased from 300M to 600M via amendment filed with Delaware Secretary of State on Oct 20, 2025.
Profusa invests another $1M in Bitcoin; reduces stockholder quorum to 33%
Second $1M investment in digital treasury assets (Bitcoin); total $2M to date.
Profusa receives Nasdaq MVLS and bid price deficiency notices; 180-day cure period
Nasdaq notified Profusa on Sep 11, 2025, that MVLS was below $50M threshold from Jul 29 to Sep 10.
Profusa stockholders approve $100M ELOC with Ascent Partners Fund
Special meeting held August 29, 2025; 17.3M shares voted, quorum achieved.
Restructured SPA into four tranches: $10M (closed July 11), $2.22M, $5.56M, $4.44M; aggregate $22.2M principal.
Profusa appoints Peter O'Rourke as lead independent director, Fred Knechtel as CFO
Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, joins board as lead independent director.
Profusa posts H1 net loss $5.1M; cash at $44K; going concern doubt persists
Net loss $2.3M for Q2 2025, $5.1M for H1 2025; no revenue; R&D $0.8M, G&A $1.6M.
Profusa strategy update: $100M ELOC secured, EU launch Q1 2026, FDA submission mid-2026
Became public on Nasdaq July 14, 2025; strategy focused on five pillars including revenue growth and AI infrastructure.
Profusa secures up to $100M equity line from Ascent Partners; proceeds to buy Bitcoin
Securities Purchase Agreement with Ascent Partners Fund LLC for up to $100M in common stock purchases.
NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.
Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.
NorthView extends business combination deadline to August 22, 2025
Stockholders approved extension of deadline for initial business combination from June 22, 2025 to August 22, 2025.
NorthView stockholders approve merger with Profusa; all proposals pass
All eight proposals approved unanimously; 4,979,599 shares voted (93.1% quorum).
NorthView buys 100K NVAC shares at $12.51 to cut redemptions; meeting adjourned to 4:30pm
Investors purchased 100,000 shares at $12.51 under non-redemption agreement to boost trust cash for Profusa merger.
NorthView enters non-redemption agreement to backstop trust account for Profusa merger
I-Bankers and Dawson James agree not to redeem shares, ensuring trust balance stays above $1.25M threshold.
NorthView Acquisition Corp. names CBIZ CPAs as new auditor after Marcum resigns
Marcum LLP resigned as independent auditor on April 30, 2025; CBIZ CPAs P.C. engaged same day.
Stockholders approved four proposals, including extending the deadline to June 22, 2025, and removing net tangible asset limitation.
Special meeting adjourned to 11:00 a.m. ET on March 21, 2025, to allow holders who redeemed shares to reverse redemptions.
NorthView amends Profusa merger terms and secures up to $20M convertible note financing
Amendment No. 4 lowers earnout revenue target for Milestone IV from $99.7M in FY2025 to $11.864M in FY2026.
Received delisting notice from Nasdaq on Dec 20, 2024 for failing to complete initial business combination within 36 months of IPO.
NorthView Acquisition Corp. receives Nasdaq notice for late Q3 filing; faces Dec 20 SPAC deadline
Received Nasdaq notice for failure to timely file Q3 10-Q (Sept 30, 2024); 60 days to submit compliance plan by Feb 4, 2025.
Nasdaq grants Northview Acquisition Corp extension to file Q2 10-Q by Nov 18, 2024
Received Extension Notice from Nasdaq on Oct 15, 2024; must file Q2 10-Q by Nov 18, 2024.
NorthView receives Nasdaq delisting notice for delayed Q2 10-Q; granted exception until Oct 14, 2024
Received Nasdaq notice on Sept 12, 2024 for failure to file Q2 2024 10-Q.
NorthView stockholders approve extension to March 2025; 50,556 shares redeemed
100% of votes in favor (5,680,199 shares) for extension, trust amendment, and adjournment.
On the effective date of the Registration Statement, Lauren Chung, Peter O’Rourke, and Ed Johnson were appointed to the board of directors of the Company.
On the effective date of the Registration Statement, Lauren Chung, Peter O’Rourke, and Ed Johnson were appointed to the board of directors of the Company.
On the effective date of the Registration Statement, Lauren Chung, Peter O’Rourke, and Ed Johnson were appointed to the board of directors of the Company.
Max materiality 0.90 · Median 0.65 · Most common event other_material